Several analysts have recently updated their ratings and price targets for Verastem (NASDAQ: VSTM):

  • 11/13/2018 – Verastem was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 11/9/2018 – Verastem was given a new $14.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 11/8/2018 – Verastem was given a new $15.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 11/7/2018 – Verastem was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 10/29/2018 – Verastem was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 10/26/2018 – Verastem was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/25/2018 – Verastem was given a new $17.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 9/25/2018 – Verastem had its price target raised by analysts at HC Wainwright to $15.00. They now have a “buy” rating on the stock.

Shares of VSTM stock opened at $5.19 on Tuesday. Verastem Inc has a 1 year low of $2.77 and a 1 year high of $10.35. The company has a market cap of $398.93 million, a PE ratio of -2.95 and a beta of 3.14. The company has a current ratio of 2.97, a quick ratio of 2.97 and a debt-to-equity ratio of 0.20.

Verastem (NASDAQ:VSTM) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.14. The company had revenue of $15.51 million for the quarter. Research analysts predict that Verastem Inc will post -1.48 EPS for the current year.

In other Verastem news, Director Michael Kauffman acquired 4,000 shares of the business’s stock in a transaction that occurred on Friday, September 28th. The shares were acquired at an average cost of $7.49 per share, for a total transaction of $29,960.00. Following the completion of the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $29,960. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert Forrester acquired 10,500 shares of the business’s stock in a transaction that occurred on Thursday, September 27th. The stock was acquired at an average price of $7.00 per share, for a total transaction of $73,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 209,234 shares of the company’s stock, valued at $1,464,638. The disclosure for this purchase can be found here. Insiders have bought 19,500 shares of company stock worth $139,420 over the last quarter. 7.06% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System acquired a new position in Verastem in the second quarter valued at approximately $100,000. HRT Financial LLC acquired a new position in Verastem in the third quarter valued at approximately $109,000. Pacer Advisors Inc. acquired a new position in Verastem in the third quarter valued at approximately $123,000. B. Riley Wealth Management Inc. acquired a new position in Verastem in the third quarter valued at approximately $127,000. Finally, Metropolitan Life Insurance Co. NY acquired a new position in Verastem in the second quarter valued at approximately $130,000. Institutional investors and hedge funds own 48.02% of the company’s stock.

Verastem, Inc, operating as a Verastem Oncology, is a biopharmaceutical company focuses on developing and commercializing medicines to improve the survival of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and is approved dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Recommended Story: Book Value Of Equity Per Share – BVPS Explained

Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with MarketBeat.com's FREE daily email newsletter.